Drugmaker UCB backs Brexit Britain with $1.3 bln investment

Belgian drugmaker UCB expects to invest about 1 billion pounds ($1.3 billion) in Britain over the next five years, throwing its support behind the country’s life sciences sector despite Brexit uncertainty.

The move is a fillip for Prime Minister Theresa May, who is battling to win support for a Dec. 11 parliamentary vote on her agreement with Brussels on Britain leaving the European Union next March.

UCB said on Wednesday that its investment would include 150 million to 200 million pounds on a purpose-built research centre. The new site will also house an early manufacturing facility and a hub for commercial operations.

The Belgian group has had a major presence in Britain since buying Slough-based antibody drug developer Celltech in 2004. However, a looming lease expiry on its current site in the town west of London prompted it to review global options.

In the event, Chief Executive Jean-Christophe Tellier said Britain came out on top as the most suitable site, thanks to its strong science culture. The decision will support 650 jobs and means the UK will remain home to one of UCB’s two global discovery research centres, with the other being in Belgium.

A year ago the British government trumpeted similar investment commitments by MSD, known as Merck & Co in the United States, and German-based diagnostics company Qiagen .

The highly regulated drugs sector is one of the most vulnerable to Britain’s decision to leave the EU because of uncertainty over how medicines oversight will function in the event of an abrupt exit.

But pharmaceutical companies are still attracted by the country’s world-class talent in biological science and its reputation as a significant centre of drug development.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 320 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 357 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra